| 000 | 01714 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250516084833.0 | ||
| 264 | 0 | _c20120618 | |
| 008 | 201206s 0 0 eng d | ||
| 022 | _a1873-5835 | ||
| 024 | 7 |
_a10.1016/j.leukres.2012.01.027 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShi, Wei | |
| 245 | 0 | 0 |
_aCombined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis. _h[electronic resource] |
| 260 |
_bLeukemia research _cJun 2012 |
||
| 300 |
_a749-55 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage |
| 650 | 0 | 4 |
_aAntigens, CD20 _ximmunology |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aHistone Deacetylase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxamic Acids _xadministration & dosage |
| 650 | 0 | 4 |
_aLymphoma, Mantle-Cell _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, SCID |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aVorinostat |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aHan, Xiaohong | |
| 700 | 1 | _aYao, Jiarui | |
| 700 | 1 | _aYang, Jianliang | |
| 700 | 1 | _aShi, Yuankai | |
| 773 | 0 |
_tLeukemia research _gvol. 36 _gno. 6 _gp. 749-55 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.leukres.2012.01.027 _zAvailable from publisher's website |
| 999 |
_c21677623 _d21677623 |
||